Marginal Zone B-Cell Lymphoma

This is a type of lymphoma, which is cancer of the lymphatic system. MALT stands for Mucosa-Associated Lymphoid Tissue. It affects the lining of organs like the stomach, salivary glands, or thyroid. It's caused by an immune system reaction to something in the body, like a virus or bacteria, that has gotten into the tissue.

Condition

What people with Marginal Zone B-Cell Lymphoma report

Every report comes from a Lived member, sent anonymously.

Have you tried Rituximab for Marginal Zone B-Cell Lymphoma?

NameHow it went

About Marginal Zone B-Cell Lymphoma

What It Is

Marginal zone lymphoma (MZL) is a slow-growing type of non-Hodgkin lymphoma, a cancer of the immune system. It starts in B cells, the white blood cells that make antibodies. Because it usually develops over months or years rather than weeks, doctors describe it as indolent, and many people live with it for a long time. It accounts for roughly 5 to 10 percent of lymphomas, and the average age at diagnosis is about 60. MZL is a family of three related diseases, and which one a person has shapes much of what follows. The most common is mucosa-associated lymphoid tissue (MALT) lymphoma, which makes up about two-thirds of cases. It grows outside the lymph nodes, most often in the stomach but also around the eye, in the skin, lungs, salivary glands or thyroid, and it often stays in one area. Nodal MZL grows in the lymph nodes. Splenic MZL mainly involves the spleen, blood and bone marrow. Symptoms depend on where the lymphoma is. In the stomach it can cause upper abdominal pain, nausea or bleeding. Splenic MZL can enlarge the spleen enough to cause fullness after small meals, along with tiredness, weight loss and low blood counts. Nodal MZL often appears as painless swollen lymph nodes. Some people have few or no symptoms until the lymphoma has grown.

Causes & Risk Factors

MZL often grows out of long-lasting immune activity. When an infection or an autoimmune disease keeps immune cells stimulated in one tissue for years, B cells there can eventually begin multiplying abnormally. The best-known example is MALT lymphoma of the stomach, which is linked to chronic infection with Helicobacter pylori (H. pylori), the same bacterium behind many stomach ulcers. Splenic MZL has been linked to hepatitis C infection, which is present in about 1 in 3 people with this type. MALT lymphoma elsewhere in the body often follows an autoimmune disease such as Sjögren syndrome, which affects the salivary and tear glands, or Hashimoto thyroiditis, an autoimmune thyroid disease. These are associations rather than certainties. Having one of these conditions does not mean lymphoma will follow, and in many people no cause is found. The infection link matters most because it can change the first treatment.

How It's Diagnosed

A biopsy is the only way to confirm MZL. A sample of the affected tissue, such as a lymph node, stomach lining taken during an upper endoscopy (a thin camera passed through the mouth), or tissue from another site, is examined under a microscope. Lab tests look for proteins on the cell surface that separate lymphoma from inflammation and from other lymphoma types. Because MZL can resemble other slow-growing lymphomas, review by a pathologist experienced in lymphoma is important. For stomach MALT lymphoma, the biopsy is also tested for H. pylori. Doctors may check the lymphoma cells for a chromosome change called t(11;18), because lymphomas that carry it are unlikely to respond to antibiotics. Staging then shows how far the lymphoma has spread. It usually involves computed tomography (CT) scans, often combined with positron emission tomography (PET/CT) to show active disease, blood tests and sometimes a bone marrow biopsy. In MZL, PET/CT detects bone marrow involvement only about a third of the time, so a marrow sample may still be taken when the result would change treatment. Blood tests for hepatitis B, hepatitis C and HIV are common, since these infections affect which treatments are safe or suitable.

Treatment Options

Not everyone with MZL needs treatment right away. When the lymphoma is not causing problems, careful monitoring, often called watch and wait, is a reasonable choice. Treatment usually starts when the lymphoma causes symptoms, bleeds, threatens an organ's function, becomes bulky or grows quickly. When an infection is driving the lymphoma, treating it often comes first. For early stomach MALT lymphoma with H. pylori, that means 10 to 14 days of antibiotics combined with a proton pump inhibitor, an acid-reducing medicine. Follow-up endoscopies check whether the bacteria are gone and the lymphoma has shrunk. About half of people show clearing within three months, while others respond more slowly over a year or more. For MZL linked to hepatitis C, antiviral treatment that clears the virus leads to partial or complete remission in roughly 40 to 60 percent of people. Lymphoma confined to one area is often treated with radiation therapy. It is the usual option for stomach lymphoma that tests negative for H. pylori or does not respond to antibiotics, and for localized MALT lymphoma around the eye, in the skin and at other sites. Surgery is sometimes used in places such as the lung, thyroid, breast or intestine. For splenic MZL, removing an enlarged spleen can relieve symptoms. Widespread or symptomatic disease is commonly treated with rituximab (Rituxan or a biosimilar version), an antibody given by infusion that attaches to a protein called CD20 on B cells and helps destroy them. It is used alone, especially for splenic MZL, or with chemotherapy such as bendamustine or chlorambucil. The choice depends on age, overall fitness and organ function: combinations with bendamustine can be hard to tolerate for older or frail people, and gentler options exist. Before rituximab, people are tested for hepatitis B, because the drug can reactivate a past infection. If MZL comes back, other options are available. Zanubrutinib (Brukinsa) is a pill that blocks BTK (Bruton tyrosine kinase), a protein that helps lymphoma B cells grow. In the US it is approved for MZL that returns after treatment with an anti-CD20 antibody such as rituximab, under an accelerated approval based on response rates. Lenalidomide (Revlimid), an oral drug related to thalidomide that acts on the immune system, is approved with rituximab for previously treated MZL. Lenalidomide can cause severe birth defects, so it must not be used during pregnancy and is dispensed only through a restricted program with pregnancy testing and contraception requirements. CAR T-cell therapy, which reprograms a person's own immune cells to attack the lymphoma, and other newer treatments are being studied for MZL, and because MZL is uncommon, clinical trials are worth asking about.

What to Expect

MZL usually follows a long course. Many people live more than 10 years after diagnosis. MALT lymphoma that stays in one area, especially in the stomach, is often controlled for a long time and is frequently curable when found early. For advanced disease, the usual goal is long periods of control rather than cure, with treatment when it is needed and monitoring in between. Watch and wait means regular visits, blood tests and sometimes scans, and after stomach MALT lymphoma, repeat endoscopies continue for years. MALT lymphoma outside the stomach comes back more often, sometimes many years later and at a different site, so long-term follow-up matters even after a good response. The outlook varies. About 1 in 5 people see the lymphoma return or grow within two years of starting treatment, and this group has a less favorable outlook. Fewer than 1 in 10 people experience transformation, a change into a faster-growing lymphoma that needs more intensive treatment.

When to Seek Help

See a doctor about swollen lymph nodes that do not go away over a few weeks, ongoing upper abdominal pain or indigestion, feeling full after small meals, or unexplained tiredness, fevers, drenching night sweats or weight loss. These symptoms more often have other causes, but persistent ones deserve evaluation. If you already have MZL, contact your care team promptly about a lymph node or lump that suddenly grows quickly, or new fevers, night sweats or weight loss, since these can signal transformation. During treatment, call your care team right away about a fever of 100.5°F (38°C) or higher or chills, because infections during cancer treatment can become serious. Vomiting blood, vomit that looks like coffee grounds, or black, tarry stools can mean bleeding in the stomach or intestine and need medical help right away. If bleeding comes with fainting, confusion, a racing heart, or cold, pale, sweaty skin, call 911.

Questions to Ask Your Doctor

  1. 1.Which type of marginal zone lymphoma do I have, and how far has it spread?
  2. 2.Could an infection such as H. pylori or hepatitis C be involved, and would treating it be the first step?
  3. 3.Do I need treatment now, or is watch and wait reasonable, and what changes would lead us to start?
  4. 4.What are the realistic goals and main side effects of the treatment you recommend, given my age and health?
  5. 5.How often will I need follow-up visits, scans or endoscopies, and what should prompt me to call before the next one?

Last reviewed • Oct 2026

Educational content, not medical advice.